C4 Therapeutics, Inc expected to post a loss of 23 cents a share - Earnings Preview
C4 Therapeutics, Inc <CCCC.OQ> expected to post a loss of 23 cents a share - Earnings Preview
C4 Therapeutics, Inc CCCC.OQ CCCC.O is expected to show a fall in quarterly revenue when it reports results on August 5 (estimated) for the period ending June 30 2026
The Watertown Massachusetts-based company is expected to report a 38.1% decrease in revenue to $4 million from $6.46 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for C4 Therapeutics, Inc is for a loss of 23 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for C4 Therapeutics, Inc is $11.00, about 216.1% above its last closing price of $3.48
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.33 | -0.37 | -0.20 | Beat | 46.2 |
Dec. 31 2026 | -0.25 | -0.30 | -0.18 | Beat | 40.7 |
Sep. 30 2025 | -0.40 | -0.41 | -0.44 | Missed | -8.3 |
Jun. 30 2025 | -0.38 | -0.38 | -0.37 | Beat | 3.6 |
Mar. 31 2025 | -0.48 | -0.45 | -0.37 | Beat | 17.8 |
Dec. 31 2024 | -0.47 | -0.48 | -0.49 | Missed | -2.6 |
Sep. 30 2024 | -0.36 | -0.38 | -0.35 | Beat | 7.9 |
Jun. 30 2024 | -0.37 | -0.37 | -0.26 | Beat | 30 |
This summary was machine generated August 3 at 13:42 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)